ResMed to double its Ireland-based software and technology team.
San Diego-headquartered digital health leader ResMed is investing €30m in R&D at its Dublin operation in a move that will create 70 new jobs over the next four years.
The roles will support innovation, technology development, and product development, including high-skilled, high-paying roles such as mobile, AWS, and full-stack software developers, and algorithm/machine learning engineers.
“Ireland has become recognised globally for the talent of our workforce, especially in the area of healthcare technology and medical devices”
“These 70 new jobs, which ResMed is creating over the next four years, alongside a commitment of €30 million investment in research and development is really welcome,” said Tánaiste and Minister for Enterprise, Trade and Employment Leo Varadkar, TD.
“Ireland has become recognised globally for the talent of our workforce, especially in the area of healthcare technology and medical devices. ResMed’s products make a real difference to so many people’s lives and it’s great Ireland is playing such an important role in that effort.”
ResMed is the world’s leading provider of connected devices, masks, and accessories for the treatment of sleep apnea, a chronic disease that affects an estimated 936 million people worldwide – including nearly 600,000 in Ireland.
Many of ResMed’s digital innovations are developed or enhanced by the company’s Ireland-based “ResMed Sensor Technologies” division.
“I’m thrilled to be in Dublin to officially open this state-of-the-art R&D facility,” said ResMed CEO Mick Farrell.
“This investment will support the continued growth of ResMed’s product portfolio to meet the needs of patients across Ireland, Europe, and the world. It will also create new capabilities and skills within our expanding team in Ireland and support our global innovation strategy.”
Mary Buckley, Executive Director of IDA Ireland added: “Continued investment in the area of Research & Development is central to IDA Ireland’s strategy ‘Driving Recovery and Sustainable Growth 2021-2024’.
“This investment by ResMed is very welcome and demonstrates the company’s commitment to Ireland. It is also an endorsement of the talented team in Dublin who have won this R&D mandate due to their track record in delivering innovative solutions.”